Doug Johnson
![Doug Johnson Doug Johnson](https://covalent-drug-discovery.com/wp-content/uploads/sites/907/2024/07/47964-Biogen-Doug-Johnson-150x150.png)
Company: Biogen
Job title: Senior Director
Seminars:
Chemoproteomic Profiling of Covalent Inhibitors in Multiple Cell Types to Assess Pharmacological Targets & Off-Target Safety Risks 9:30 am
Chemoproteomic profiling using clickable probes of covalent inhibitors in multiple cell types is a crucial technique for evaluating their proteome-wide selectivity to assess target engagement and off-targets Importance of selecting appropriate cell lines and organ systems for screening covalent inhibitors to comprehensively assess potential off-target toxicities While no single method can definitively determine a compound’s…Read more
day: Conference Day Two